BriSTAR Immunotech

Focus: BriSTAR Immunotech is an early-stage cell therapy company focused on STAR-T cell therapies for hematologic malignancies, based in Beijing and founded in 2023. The company operates as a pre-revenue biotech entity with a single Phase 1 program in its pipeline.

Gene Therapy Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About BriSTAR Immunotech

AI assessmentNot Hiring

No open roles listed right now. Follow BriSTAR Immunotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

LILRB4 STAR-T cells

Relapsed/Refractory Acute Myeloid Leukemia and Chronic Granulocytic-Mononocytic Leukemia

Phase 1

Clinical Trials (1)

NCT05548088LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML

Phase 1

Help build intelligence for BriSTAR Immunotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity to build a cell therapy platform from inception with differentiated LILRB4 STAR-T cell approach in underserved hematologic malignancies
Access to the rapidly growing Chinese biotech ecosystem and potential regulatory pathways in Asia, including potential accelerated development programs
Early-stage equity upside potential for founders and early employees joining a well-capitalized immunotherapy company at formative stages

Watch Out For

No active hiring (0 open roles) signals the company may be in stealth mode or consolidating founding team, limiting near-term employment opportunities
Pre-clinical revenue and single Phase 1 trial create execution risk; company is 2+ years away from material pipeline progression milestones
Limited public disclosure on funding, employee count, and capitalization makes due diligence on financial stability and runway difficult

Generated by Claude from BriSTAR Immunotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 1 clinical trial

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline